Sun Pharmaceutical, India’s pharma powerhouse, is rewriting history with its blockbuster $11.75 billion acquisition of American firm Organon. Priced at roughly 1.10 lakh crore rupees, this all-cash transaction at $14 per share represents the biggest M&A move ever by an Indian drug company.
Announced via stock exchange disclosures, the deal fortifies Sun Pharma’s strategy to amplify its innovative drug pipeline, reinforce branded generics, and storm the biosimilars market as a global frontrunner.
New Jersey’s Organon specializes in women’s health, biosimilars, and legacy drugs, commanding a portfolio of 70+ products across 140+ nations. For the fiscal year to December 2025, it posted $6.2 billion revenue and $1.9 billion adjusted EBITDA, setting the stage for the merged outfit’s projected $12.4 billion top-line and entry into the top 25 pharma ranks.
The boards of both firms have approved the pact, subject to regulatory and shareholder clearances, with completion slated for early 2027. Sun Pharma plans to finance it via internal cash and borrowings.
Investor sentiment soared, propelling Sun Pharma stock up 7.5% to 1,741 rupees around 10:50 AM. This merger promises synergies in high-growth areas like women’s health, positioning the Indian firm for exponential growth amid intensifying global competition.
As Sun Pharma eyes this pivotal expansion, stakeholders watch closely how it navigates integration challenges to unlock value in diverse therapeutic domains.
